Gosset research

Reports

Catalyst forecasts, competitive landscapes, conference coverage, worked examples and research articles, newest first. Every item links to the report itself.

Landscapes

The programs, evidence and deals around a target or disease.

All landscapes
  1. Landscape

    Huntington’s disease: search and evaluation

    A screen of the assets in development for Huntington’s disease, with the context to weigh their potential.

  2. Landscape

    Claudin 18.2 research landscape

    Source-linked programs, patient populations, clinical results and rights across antibodies, ADCs and cell therapies.

    Undated

  3. Landscape

    TL1A research landscape

    TL1A biology in inflammatory bowel disease, the Merck, Roche and Sanofi-Teva Phase 3 race, clinical evidence, patents and deals.

    Undated

Catalysts

Forecasts of a trial’s chance of success, ahead of its readout.

  1. Catalyst

    Halneuron: ahead of Phase 2b results

    A Gosset PTRS forecast for chemotherapy-induced neuropathic pain, with comparable trials and the evidence behind the estimate.

Conferences

Key results and trends from medical meetings, by therapeutic area.

  1. Conference

    ASH 2026: hematology readouts

    55 selected hematology readouts, with highlights, efficacy and safety charts, patient settings and original sources. Abstract-release preview.

  2. Conference

    ESMO 2026: oncology readouts

    Explore clinical results, ADC programs and emerging oncology approaches, with source-linked charts and trial context.

  3. Conference

    Cardiology conferences

    Key results and trends from 1 meeting: ESC.

  4. Conference

    Dermatology conferences

    Key results and trends from 2 meetings: EADV, AAD.

  5. Conference

    Endocrinology & Metabolism conferences

    Key results and trends from 3 meetings: ENDO, ADA, EASD.

  6. Conference

    Gastroenterology conferences

    Key results and trends from 3 meetings: DDW, AASLD, EASL.

  7. Conference

    Hematology conferences

    Key results and trends from 2 meetings: ASH, EHA.

  8. Conference

    Immunology conferences

    Key results and trends from 3 meetings: EULAR, ACR, AAAAI.

  9. Conference

    Nephrology conferences

    Key results and trends from 2 meetings: ASN, ERA.

  10. Conference

    Neurology conferences

    Key results and trends from 2 meetings: AAN, ECTRIMS.

  11. Conference

    Oncology conferences

    Key results and trends from 10 meetings: AACR, ASCO, ESMO, WCLC, SITC, ASCO GU, ASCO GI, ESMO Asia, ESMO GI, ELCC.

  12. Conference

    Ophthalmology conferences

    Key results and trends from 2 meetings: ARVO, EURETINA.

  13. Conference

    Pulmonology conferences

    Key results and trends from 3 meetings: ATS, ERS, CHEST.

Worked examples

Research questions answered with Gosset, step by step.

All worked examples
  1. Worked example

    Phase 1 trials of B7-H3-targeted drugs

    Every Phase 1 and Phase 1/2 trial of a B7-H3-directed drug, with modality, tumour type, geography and status.

  2. Worked example

    Claudin 18.2 competitive landscape

    Claudin 18.2 programs from preclinical to approval, with program profiles, trial sources and licensing context.

  3. Worked example

    China-to-US ADC licensing

    China-origin ADCs in Phase 2 or 3 and their US licensing partners, with phases and downloadable data.

Research articles

Assessments of individual assets and market questions.

All research articles
  1. Research article

    DT120: off-patent LSD, reworked into a $4.4B psychiatry bet

    Definium’s single-dose lysergide after a strong GAD Phase 2b and a positive MDD Phase 3: the moat, modeled odds and rNPV.

  2. Research article

    Most of XBI’s +78% is sector beta, not new money

    A factor model and deal-flow data split the small-cap biotech index’s one-year run, leaving M&A the one outside-money channel.

  3. Research article

    Tegoprubart: a CNI-free bet on tolerability in kidney transplant

    Eledon’s anti-CD40L antibody missed its Phase 2 efficacy endpoint yet separated sharply from tacrolimus on safety.

Reports

Asset, disease and clinical reports, including sample deliverables.

All reports
  1. Report

    HCXT-2001: oral IL-23R inhibition

    Inside the oral IL-23R program behind Gilead’s announced acquisition agreement: mechanism, clinical evidence and competition.

  2. Report · External · Slide deck

    Asset due diligence: Frexalimab for relapsing multiple sclerosis (opens Slide deck on Google Drive)

    Full due-diligence assessment of a drug asset: thesis, evidence, competitive landscape, IP, pricing, and risks.

    External sample

  3. Report · External · Slide deck

    Disease brief: IgA nephropathy (opens Slide deck on Google Drive)

    A business development brief for a disease: unmet need, epidemiology, pipeline & competition, deals, and risk.

    External sample

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call